company background image
1099

Sinopharm GroupSEHK:1099 Stock Report

Market Cap

HK$65.5b

7D

-7.6%

1Y

11.2%

Updated

25 Oct, 2021

Data

Company Financials +
1099 fundamental analysis
Snowflake Score
Valuation5/6
Future Growth1/6
Past Performance4/6
Financial Health3/6
Dividends5/6

1099 Overview

Sinopharm Group Co. Ltd., together with its subsidiaries, engages in the wholesale and retail of pharmaceutical and medical devices and healthcare products in the People’s Republic of China.

Sinopharm Group Competitors

Shanghai Fosun Pharmaceutical (Group)

SHSE:600196

CN¥122.3b

Price History & Performance

Summary of all time highs, changes and price drops for Sinopharm Group
Historical stock prices
Current Share PriceHK$19.82
52 Week HighHK$17.04
52 Week LowHK$28.00
Beta0.79
1 Month Change-2.12%
3 Month Change-1.88%
1 Year Change11.22%
3 Year Change-46.21%
5 Year Change-47.50%
Change since IPO7.02%

Recent News & Updates

Sep 23
These 4 Measures Indicate That Sinopharm Group (HKG:1099) Is Using Debt Reasonably Well

These 4 Measures Indicate That Sinopharm Group (HKG:1099) Is Using Debt Reasonably Well

The external fund manager backed by Berkshire Hathaway's Charlie Munger, Li Lu, makes no bones about it when he says...

Sep 10
A Look At The Fair Value Of Sinopharm Group Co., Ltd. (HKG:1099)

A Look At The Fair Value Of Sinopharm Group Co., Ltd. (HKG:1099)

Today we will run through one way of estimating the intrinsic value of Sinopharm Group Co., Ltd. ( HKG:1099 ) by...

Aug 28
Return Trends At Sinopharm Group (HKG:1099) Aren't Appealing

Return Trends At Sinopharm Group (HKG:1099) Aren't Appealing

Did you know there are some financial metrics that can provide clues of a potential multi-bagger? In a perfect world...

Jun 13
Sinopharm Group (HKG:1099) Is Increasing Its Dividend To HK$0.84

Sinopharm Group (HKG:1099) Is Increasing Its Dividend To HK$0.84

Sinopharm Group Co., Ltd. ( HKG:1099 ) will increase its dividend on the 10th of August to HK$0.84. This will take the...

Shareholder Returns

1099HK HealthcareHK Market
7D-7.6%1.0%2.1%
1Y11.2%-43.7%5.9%

Return vs Industry: 1099 exceeded the Hong Kong Healthcare industry which returned -43.7% over the past year.

Return vs Market: 1099 exceeded the Hong Kong Market which returned 5.9% over the past year.

Price Volatility

Is 1099's price volatile compared to industry and market?
1099 volatility
1099 Beta0.79
Industry Beta0.88
Market Beta1

Stable Share Price: 1099 is less volatile than 75% of Hong Kong stocks over the past 3 months, typically moving +/- 4% a week.

Volatility Over Time: 1099's weekly volatility (4%) has been stable over the past year.

About the Company

FoundedEmployeesCEOWebsite
2003108,370Yong Liuhttps://www.sinopharmgroup.com.cn

Sinopharm Group Co. Ltd., together with its subsidiaries, engages in the wholesale and retail of pharmaceutical and medical devices and healthcare products in the People’s Republic of China. The company operates through four segments: Pharmaceutical Distribution, Medical Devices, Retail Pharmacy, and Other Business. The Pharmaceutical Distribution segment distributes pharmaceutical products to hospitals, other distributors, retail drug stores, and clinics.

Sinopharm Group Fundamentals Summary

How do Sinopharm Group's earnings and revenue compare to its market cap?
1099 fundamental statistics
Market CapCN¥53.83b
Earnings (TTM)CN¥7.87b
Revenue (TTM)CN¥501.77b

6.5x

P/E Ratio

0.1x

P/S Ratio

Earnings & Revenue

Key profitability statistics from the latest earnings report
1099 income statement (TTM)
RevenueCN¥501.77b
Cost of RevenueCN¥458.10b
Gross ProfitCN¥43.67b
ExpensesCN¥35.79b
EarningsCN¥7.87b

Last Reported Earnings

Jun 30, 2021

Next Earnings Date

n/a

Earnings per share (EPS)2.52
Gross Margin8.70%
Net Profit Margin1.57%
Debt/Equity Ratio88.2%

How did 1099 perform over the long term?

See historical performance and comparison

Dividends

4.2%

Current Dividend Yield

27%

Payout Ratio

Valuation

Is Sinopharm Group undervalued compared to its fair value and its price relative to the market?

10.5%

Undervalued compared to fair value


Share Price vs. Fair Value

Below Fair Value: 1099 (HK$19.82) is trading below our estimate of fair value (HK$22.15)

Significantly Below Fair Value: 1099 is trading below fair value, but not by a significant amount.


Price To Earnings Ratio

PE vs Industry: 1099 is good value based on its PE Ratio (6.5x) compared to the Hong Kong Healthcare industry average (16.9x).

PE vs Market: 1099 is good value based on its PE Ratio (6.5x) compared to the Hong Kong market (9.7x).


Price to Earnings Growth Ratio

PEG Ratio: 1099 is good value based on its PEG Ratio (0.8x)


Price to Book Ratio

PB vs Industry: 1099 is good value based on its PB Ratio (0.9x) compared to the HK Healthcare industry average (1.7x).


Future Growth

How is Sinopharm Group forecast to perform in the next 1 to 3 years based on estimates from 16 analysts?

8.4%

Forecasted annual earnings growth


Earnings and Revenue Growth Forecasts


Analyst Future Growth Forecasts

Earnings vs Savings Rate: 1099's forecast earnings growth (8.4% per year) is above the savings rate (1.5%).

Earnings vs Market: 1099's earnings (8.4% per year) are forecast to grow slower than the Hong Kong market (17.7% per year).

High Growth Earnings: 1099's earnings are forecast to grow, but not significantly.

Revenue vs Market: 1099's revenue (7.5% per year) is forecast to grow slower than the Hong Kong market (12.5% per year).

High Growth Revenue: 1099's revenue (7.5% per year) is forecast to grow slower than 20% per year.


Earnings per Share Growth Forecasts


Future Return on Equity

Future ROE: 1099's Return on Equity is forecast to be low in 3 years time (9%).


Past Performance

How has Sinopharm Group performed over the past 5 years?

10.3%

Historical annual earnings growth


Earnings and Revenue History

Quality Earnings: 1099 has high quality earnings.

Growing Profit Margin: 1099's current net profit margins (1.6%) are higher than last year (1.4%).


Past Earnings Growth Analysis

Earnings Trend: 1099's earnings have grown by 10.3% per year over the past 5 years.

Accelerating Growth: 1099's earnings growth over the past year (27.5%) exceeds its 5-year average (10.3% per year).

Earnings vs Industry: 1099 earnings growth over the past year (27.5%) underperformed the Healthcare industry 29.5%.


Return on Equity

High ROE: 1099's Return on Equity (14.3%) is considered low.


Financial Health

How is Sinopharm Group's financial position?


Financial Position Analysis

Short Term Liabilities: 1099's short term assets (CN¥300.0B) exceed its short term liabilities (CN¥232.3B).

Long Term Liabilities: 1099's short term assets (CN¥300.0B) exceed its long term liabilities (CN¥18.8B).


Debt to Equity History and Analysis

Debt Level: 1099's debt to equity ratio (88.2%) is considered high.

Reducing Debt: 1099's debt to equity ratio has increased from 79.5% to 88.2% over the past 5 years.

Debt Coverage: 1099's debt is not well covered by operating cash flow (13.4%).

Interest Coverage: 1099's interest payments on its debt are well covered by EBIT (7.2x coverage).


Balance Sheet


Dividend

What is Sinopharm Group current dividend yield, its reliability and sustainability?

4.24%

Current Dividend Yield


Dividend Yield vs Market

Notable Dividend: 1099's dividend (4.24%) is higher than the bottom 25% of dividend payers in the Hong Kong market (2.22%).

High Dividend: 1099's dividend (4.24%) is low compared to the top 25% of dividend payers in the Hong Kong market (6.77%).


Stability and Growth of Payments

Stable Dividend: 1099's dividends per share have been stable in the past 10 years.

Growing Dividend: 1099's dividend payments have increased over the past 10 years.


Current Payout to Shareholders

Dividend Coverage: With its reasonably low payout ratio (27.4%), 1099's dividend payments are well covered by earnings.


Future Payout to Shareholders

Future Dividend Coverage: 1099's dividends in 3 years are forecast to be well covered by earnings (19.7% payout ratio).


Next Steps

Management

How experienced are the management team and are they aligned to shareholders interests?

3.3yrs

Average management tenure


CEO

Yong Liu (52 yo)

3.92yrs

Tenure

CN¥6,605,000

Compensation

Mr. Yong Liu serves as the Chief Legal Advisor at Sinopharm Group Co. Ltd. and served as its Joint Company Secretary since October 28, 2016 until August 24, 2018. Mr. Liu is Executive Director of Sinopharm...


CEO Compensation Analysis

Compensation vs Market: Yong's total compensation ($USD1.03M) is above average for companies of similar size in the Hong Kong market ($USD685.86K).

Compensation vs Earnings: Yong's compensation has been consistent with company performance over the past year.


Leadership Team

Experienced Management: 1099's management team is considered experienced (3.3 years average tenure).


Board Members

Experienced Board: 1099's board of directors are not considered experienced ( 2.5 years average tenure), which suggests a new board.


Ownership

Who are the major shareholders and have insiders been buying or selling?


Insider Trading Volume

Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.


Recent Insider Transactions

Ownership Breakdown

Dilution of Shares: Shareholders have not been meaningfully diluted in the past year.


Top Shareholders

Company Information

Sinopharm Group Co., Ltd.'s employee growth, exchange listings and data sources


Key Information

  • Name: Sinopharm Group Co., Ltd.
  • Ticker: 1099
  • Exchange: SEHK
  • Founded: 2003
  • Industry: Health Care Distributors
  • Sector: Healthcare
  • Market Cap: HK$65.534b
  • Shares outstanding: 3.12b
  • Website: https://www.sinopharmgroup.com.cn

Number of Employees


Location

  • Sinopharm Group Co., Ltd.
  • Sinopharm Group Building
  • No. 385, East Longhua Road
  • Shanghai
  • 200023
  • China

Listings


Company Analysis and Financial Data Status

All financial data provided by Standard & Poor's Capital IQ.
DataLast Updated (UTC time)
Company Analysis2021/10/25 10:03
End of Day Share Price2021/10/25 00:00
Earnings2021/06/30
Annual Earnings2020/12/31


Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.